Clinical Trials Browser

Phase 2 × entinostat × Clear all

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Phase 2 Terminated

5 enrolled 9 charts

Recurrence, Neuroendocrine Tumors

NCT07441486 2026-03-02

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07235618 2025-11-19

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT03978624 2025-10-15

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Phase 2 Active not recruiting

20 enrolled 11 charts

Urinary Bladder Neoplasms

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Phase 2 Active not recruiting

Lymphoma, Recurrence

NCT03250273 2025-05-28

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Phase 2 Completed

44 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Cholangiocarcinoma

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Phase 2 Completed

58 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03552380 2024-09-03

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Phase 2 Terminated

12 enrolled 16 charts

Carcinoma, Renal Cell

NCT03765229 2024-01-10

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Phase 2 Completed

11 enrolled 12 charts

Melanoma

NCT02697630 2023-12-08

PEMDAC

Phase 2 Completed

Uveal Melanoma

NCT03501381 2023-09-01

High Dose IL 2 and Entinostat in RCC

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT00750698 2023-07-06

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Phase 2 Terminated

8 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03291886 2022-06-21

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01234532 2022-05-03

0927GCC

Phase 2 Terminated

5 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00866333 2019-10-22

ENGAGE-501

Phase 2 Terminated

49 enrolled 12 charts

Hodgkin Disease

NCT01207726 2019-02-05

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Phase 2 Terminated

13 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung

NCT01935947 2018-07-27

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

17 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00185302 2015-12-14

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT02115594 2014-10-08

ENCORE305

Phase 2 Withdrawn

Breast Neoplasms

NCT01105377 2014-08-01

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

47 enrolled 6 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms